DelveInsight’s “Checkpoint Inhibitors Competitive landscape 2026” analysis delivers detailed perspectives on 50+ organizations and 60+ therapeutics in the Checkpoint Inhibitors Competitive arena. It encompasses the Checkpoint Inhibitors Treatment evaluation by product classification, development phase, administration route, and molecular classification. It further emphasizes the inactive pipeline candidates within this therapeutic space.
Discover the comprehensive insights into the evolving Checkpoint Inhibitors Pipeline @ Checkpoint Inhibitors Competitive Landscape Report
Essential Highlights from the Checkpoint Inhibitors Competitive Analysis
- On March 25, 2026- Centre Leon Berard commenced a phase III investigation aimed at comparing the survival of individuals suffering from MSI-H/dMMR locally advanced or metastatic oesophagogastric adenocarcinoma managed by bi-immunotherapy (experimental arm) versus standard current management (FOLFOX/XELOX + nivolumab: standard arm).
- On March 13, 2026- Ipsen announced a phase II investigation to assess the efficacy and safety of cabozantinib as 2nd line management in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who experienced progression after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
- The prominent Checkpoint Inhibitors Organizations include CanBas Co. Ltd, Boundless Bio, Sumitomo Pharma America Inc., Pharos I&BT Co, Virion Therapeutics, OncoC4 Transcode Therapeutics Inc., and additional entities.
- Encouraging Checkpoint Inhibitors Treatments include Ipilimumab Injection, Durvalumab, Methotrexate, Vinblastine, Atezolizumab, Antibiotics, Indoximod, and additional candidates.
Access comprehensive examination of the Checkpoint Inhibitors Competitive Landscape 2026 @ Checkpoint Inhibitors Research and Development Report
Checkpoint Inhibitors Commercialized Treatments
Bristol Myers Squibb/ Ono Pharmaceuticals
Bristol Myers Squibb (BMS) operates as an international biopharmaceutical corporation concentrated on discovering, developing, and delivering innovative pharmaceutical agents. With a robust presence in oncology, immunology, cardiovascular, and fibrosis, BMS aims to address critical medical requirements. The corporation leverages advanced science and technology to develop treatments that enhance patient outcomes. BMS maintains a diverse pipeline of therapies, with a commitment to sustainability and social responsibility. Headquartered in New York, BMS operates internationally, partnering with various healthcare stakeholders to advance global health.
Opdivo
Opdivo represents a programmed death-1 (PD-1) immune checkpoint inhibitor engineered to uniquely harness the organism’s own immune system to facilitate restoration of anti-tumor immune response. By harnessing the organism’s own immune system to combat cancer, Opdivo has emerged as an important therapeutic alternative across multiple malignancies. Opdivo’s prominent global development initiative is founded on Bristol Myers Squibb’s scientific expertise in the domain of Immuno-Oncology and encompasses a comprehensive range of clinical investigations across all phases, including Phase 3, in a variety of tumor classifications. To date, the Opdivo clinical development initiative has enrolled more than 35,000 individuals. The Opdivo investigations have contributed to gaining a deeper understanding of the potential role of biomarkers in patient management, particularly regarding how individuals may benefit from Opdivo across the continuum of PD-L1 expression. In July 2014, Opdivo was the inaugural PD-1 immune checkpoint inhibitor to receive regulatory authorization anywhere internationally. Opdivo is currently authorized in more than 65 nations, including the United States, the European Union, Japan and China. In October 2015, the Company’s Opdivo and Yervoy combination regimen was the inaugural Immuno-Oncology combination to receive regulatory authorization for the management of metastatic melanoma and is currently authorized in more than 50 nations, including the United States and the European Union.
Genentech
Genentech, a member of the Roche Group, operates as a prominent biotechnology corporation headquartered in South San Francisco, California. Established in 1976, it pioneered the biotech sector with the advancement of recombinant DNA technology. Genentech concentrates on innovative treatments in oncology, immunology, neuroscience, and ophthalmology. It has developed breakthrough biologics including Herceptin, Avastin, Rituxan, and Tecentriq. The corporation emphasizes a science-driven methodology and robust R&D pipeline. As a component of Roche since 2009, Genentech continues to function as an independent research and early development center.
Atezolizumab
Atezolizumab (commercial name: Tecentriq) represents a monoclonal antibody and immune checkpoint inhibitor developed by Genentech/Roche. It targets PD-L1 (programmed death-ligand 1), restoring T-cell activity to facilitate the immune system in detecting and destroying malignant cells. Atezolizumab is authorized for multiple malignancies, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), urothelial carcinoma, and hepatocellular carcinoma (HCC). It can be utilized as monotherapy or in combination with chemotherapy or targeted treatments. Administered intravenously, it is generally well tolerated but may precipitate immune-related adverse events. Tecentriq has emerged as a key agent in the evolving domain of cancer immunotherapy.
Checkpoint Inhibitors Pipeline Treatments
OncoC4
OncoC4 operates as a clinical-stage biopharmaceutical corporation focused on developing innovative immunotherapies for cancer management. The corporation’s principal product candidate represents a monoclonal antibody targeting the CTLA-4 immune checkpoint, aiming to enhance the organism’s immune response against tumors. OncoC4’s research and development initiatives are centered on advancing therapies that demonstrate potential to improve outcomes for individuals with various malignancies. The corporation is committed to leveraging advanced science and technology to address critical unmet requirements in oncology. Headquartered in the United States, OncoC4 partners with industry leaders to further its mission of transforming cancer care.
ONC-841
ONC-841 represents a humanized antagonist anti-SIGLEC10 monoclonal antibody. It is the inaugural SIGLEC10 antagonist to enter clinical development. Siglec10 represents an inhibitory receptor gene broadly expressed in tumor-infiltrating immune cells that performs an important function in tumor evasion of the immune system through its interaction with CD24 present on tumor cells. ONC-841 blocks this interaction, enabling anti-tumor activation of immune cells including NK cells, macrophages and T cells. SIGLEC10 possesses an authentic immunoreceptor tyrosine-based inhibitory motif, which is distinct from other siglecs such as SIGLEC15. In preclinical investigations ONC-841 has demonstrated increased phagocytosis of malignant cells and improved function of tumor-infiltrating T cells and innate cells, as well as enhanced antibody-dependent CD16a signaling, a surrogate for antibody-dependent cell mediated cytotoxicity (ADCC). Presently the therapeutic is in Phase I phase of its development for the management of advanced solid tumors.
Kyowa Kirin
Boundless Bio operates as a clinical-stage oncology corporation dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet requirement of individuals with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer individuals. Boundless Bio is developing the inaugural ecDNA-directed therapeutic candidates (ecDTx), BBI-355, which represents an oral inhibitor of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2 clinical investigation in cancer individuals with oncogene amplifications. Boundless Bio’s second ecDTx, BBI-825, represents an oral inhibitor of ribonucleotide reductase (RNR) being evaluated in a Phase 1/2 clinical investigation in colorectal cancer individuals with BRAFV600E or KRASG12C mutations and resistance gene amplifications. Leveraging its Spyglass platform, Boundless Bio maintains an additional program (ecDTx 3) advancing through preclinical development and discovery. Boundless Bio is headquartered in San Diego, CA.
BBI-355
BBI-355 represents a novel, oral, selective small molecule inhibitor of checkpoint kinase 1 (CHK1) being investigated in the ongoing, first-in-human, Phase 1/2 POTENTIATE clinical investigation (NCT05827614) in cancer individuals with oncogene amplifications. CHK1 represents a master regulator of cells’ response to replication stress (RS). RS is elevated in malignant cells with oncogene amplification, including on ecDNA, and, because of this, represents a key vulnerability of those cells. BBI-355 was engineered to exploit the elevated RS in ecDNA-enabled oncogene amplified malignant cells by disrupting proper CHK1 function in regulating RS and thereby facilitating catastrophic RS to preferentially eliminate malignant cells relative to healthy cells.
OncoC4
OncoC4, Inc. operates as a privately held, clinical-stage biopharmaceutical corporation headquartered in Rockville, Maryland. Established in 2020 by immunologists Dr. Yang Liu and Dr. Pan Zheng, the corporation is dedicated to developing next-generation immunotherapies targeting both innate and adaptive immune checkpoints, such as CTLA-4, CD24, and Siglecs. Its principal asset, gotistobart (ONC-392), a novel anti-CTLA-4 antibody, is being co-developed with BioNTech for multiple solid tumor indications. The corporation’s pipeline additionally includes ONC-841, an anti-Siglec-10 monoclonal antibody currently in Phase 1 investigations for solid tumors. In 2024, OncoC4 expanded its capabilities by merging with AcroImmune, acquiring assets including AI-081, a PD-1/VEGF bispecific antibody, and establishing in-house clinical manufacturing facilities.
ONC-841
ONC-841 represents an investigational, first-in-class humanized monoclonal antibody developed by OncoC4, Inc. It targets SIGLEC10, an immune checkpoint receptor that enables tumor cells to evade immune detection by interacting with CD24. By blocking this interaction, ONC-841 aims to rejuvenate anti-tumor immune responses from T cells, NK cells, and macrophages within the tumor microenvironment. A Phase 1 clinical investigation (NCT06352359) is currently underway in the U.S., evaluating ONC-841 as a monotherapy in individuals with advanced or metastatic solid tumors. Initial safety, pharmacokinetics, and efficacy data are anticipated in 2025. If successful, ONC-841 could represent a novel approach in cancer immunotherapy by targeting innate immune checkpoints.
Transcode Therapeutics, inc
TransCode Therapeutics, Inc. operates as a Boston-based clinical-stage biopharmaceutical corporation established in 2016, focused on developing RNA-based therapies to manage metastatic cancer. The corporation’s proprietary TTX platform enables targeted delivery of therapeutic RNA molecules to previously undruggable genetic targets within tumor cells. Its principal candidate, TTX-MC138, targets microRNA-10b, a key regulator of metastasis in malignancies such as breast, pancreatic, and glioblastoma. Other pipeline programs include TTX-siPDL1, an siRNA therapeutic modulating PD-L1 expression, and TTX-RIGA, an RNA-based agonist of RIG-I to activate innate immunity in the tumor microenvironment. TransCode is additionally advancing TTX-CRISPR and TTX-mRNA platforms for gene editing and cancer vaccine development, respectively. The corporation partners with institutions including the University of Texas MD Anderson Cancer Center to accelerate its research and development initiatives.
TTX-siPDL1
TTX-siPDL1 represents an investigational RNA interference (RNAi) therapeutic developed by TransCode Therapeutics to target programmed death-ligand 1 (PD-L1) in solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC). Unlike traditional monoclonal antibodies that block PD-L1 at the protein level, TTX-siPDL1 employs small interfering RNA (siRNA) to silence PD-L1 gene expression post-transcriptionally, thereby reducing PD-L1 production within tumor cells.
Acquire strategic intelligence on Checkpoint Inhibitors Investigational Treatments, pipeline highlights, and competitive trends shaping the market @ Checkpoint Inhibitors Preclinical and Discovery Stage Candidates
Checkpoint Inhibitors Analytical Framework by DelveInsight
In-depth Commercial Evaluation: Checkpoint Inhibitors Partnership Examination by Organizations
The Analysis delivers comprehensive commercial evaluation of therapeutics that have been incorporated, which comprises collaboration, agreement, licensing and acquisition – deal value trends. The sub-segmentation is described in the analysis which provides organization-organization collaboration (licensing/partnering), organization academic collaboration and acquisition examination in tabulated format.
Checkpoint Inhibitors Competitive Landscape
The analysis comprises comparative evaluation of Organizations (by therapy, development phase, and technology).
Checkpoint Inhibitors Analysis Evaluation
- Organization Examination
- Therapeutic Evaluation
- Pipeline Evaluation
- Inactive therapeutics assessment
- Unmet Requirements
Download the comprehensive pipeline and competitive landscape analysis @ Checkpoint Inhibitors Market Catalysts and Challenges
Scope of the Checkpoint Inhibitors Competitive Analysis
- Coverage- Global
- Checkpoint Inhibitors Organizations- CanBas Co. Ltd, Boundless Bio, Sumitomo Pharma America Inc., Pharos I&BT Co, Virion Therapeutics, OncoC4 Transcode Therapeutics Inc., and additional entities.
- Checkpoint Inhibitors Treatments- Ipilimumab Injection, Durvalumab, Methotrexate, Vinblastine, Atezolizumab, Antibiotics, Indoximod, and additional candidates.
- Checkpoint Inhibitors Commercialized Treatments and Pipeline Treatments
- Checkpoint Inhibitors Preclinical and Discovery Stage Candidates, Unmet Requirements
Understand the Checkpoint Inhibitors Organizations, therapeutics, and market dynamics driving the Checkpoint Inhibitors Analysis in 2026 @ Checkpoint Inhibitors Mechanism of Action and Unmet Requirements
Table of Contents
- Introduction
- Executive Overview
- Checkpoint Inhibitors: Overview
- Checkpoint Inhibitors -Analytical Framework: In-depth Commercial Evaluation
- Competitive Landscape
- Therapeutic Evaluation
- Checkpoint Inhibitors: Organization and Product Profiles (Commercialized Treatments)
- Bristol Myers Squibb/ Ono Pharmaceuticals
- Opdivo
- Checkpoint Inhibitors: Organization and Product Profiles (Pipeline Treatments)
- Advanced Stage Candidates (Phase III)
- Company Name
- Drug Name
- Intermediate-Stage Candidates (Phase II)
- CanBas Co. Ltd.
- CBP 501
- Initial Stage Candidates (Phase I)
- OncoC4
- ONC-841
- Preclinical and Discovery Stage Candidates
- Company Name
- Product Name
- Inactive Candidates
- Checkpoint Inhibitors- Unmet requirements
- Checkpoint Inhibitors – Market catalysts and challenges
- Appendix
About Us
DelveInsight operates as a prominent healthcare-focused market research and consulting organization that delivers clients with superior market intelligence and examination to facilitate informed business strategies. With a team of seasoned industry specialists and comprehensive understanding of the life sciences and healthcare domains, we provide customized research solutions and perspectives to clients worldwide. Connect with us to obtain superior, accurate, and real-time intelligence to maintain competitive advantage.
Contact Us
Kanishk
kkumar@delveinsight.com
